Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CYP2J2 | P51589 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14436547 | 0.81 | HSD17B10 (0.44) | HSD11B1HTTSMN1; SMN2CYP2D6KCNH2 | |
| SCHEMBL29326474 | 0.80 | ITGB3 (0.43) | GLAKDM1ASMN1; SMN2CYP2D6CYP1A2 | |
| SCHEMBL17281926 | 0.79 | CYP2J2 (0.45) | HSD11B1CYP2J2POLBHTTSMN1; SMN2 | |
| SCHEMBL5132271 | 0.79 | POLB (0.62) | GLAPOLBHTTKDM1ASMN1; SMN2 | |
| SCHEMBL11155988 | 0.77 | GLA (0.50) | GLAPOLBHTTKDM1ASMN1; SMN2 | |
| SCHEMBL13602692 | 0.76 | CYP2D6 (0.36) | HSD11B1CYP2J2POLBHTTSMN1; SMN2 | |
| SCHEMBL30713417 | 0.76 | CYP2D6 (0.46) | HSD11B1CYP2D6KCNH2HRH3 | |
| SCHEMBL17988092 | 0.76 | GLA (0.46) | GLAPOLBHTTKDM1ASMN1; SMN2 | |
| SCHEMBL3197443 | 0.76 | GLA (0.53) | GLAPOLBHTTKDM1ASMN1; SMN2 | |
| SCHEMBL179340 | 0.76 | SLC18A3 (0.43) | HSD11B1POLBHTTKDM1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172549-A1 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-8431593-B2 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-8431593-B2 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | H. LUNDBECK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216763-A1 | Heteroaryl Amide Derivatives | HCAR2, PIGS, GPR52 | GLA 1825/4885HSD11B1 2330/4885CYP2J2 391/4885 |
| US-20130172549-A1 | Heteroaryl amide derivatives | HCAR2, PIGS, GPR52 | GLA 1825/4885HSD11B1 2330/4885CYP2J2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.